Molecular basis of mitochondrial fatty acid oxidation defects.

A dozen separate inherited disorders of mitochondrial fatty acid beta-oxidation have been described in humans. This represents about half of the potential sites for genetic error that can affect this important pathway of energy metabolism. As the characterization of these disorders at the clinical a...

Full description

Bibliographic Details
Main Authors: PM Coates, K Tanaka
Format: Article
Language:English
Published: Elsevier 1992-08-01
Series:Journal of Lipid Research
Online Access:http://www.sciencedirect.com/science/article/pii/S002222752040762X
id doaj-172d1f60085046279d00000b203f1af8
record_format Article
spelling doaj-172d1f60085046279d00000b203f1af82021-04-26T05:51:31ZengElsevierJournal of Lipid Research0022-22751992-08-0133810991110Molecular basis of mitochondrial fatty acid oxidation defects.PM Coates0K Tanaka1Division of Gastroenterology, Nutrition, and Lipid-Heart Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104.Division of Gastroenterology, Nutrition, and Lipid-Heart Research, Children's Hospital of Philadelphia, Philadelphia, PA 19104.A dozen separate inherited disorders of mitochondrial fatty acid beta-oxidation have been described in humans. This represents about half of the potential sites for genetic error that can affect this important pathway of energy metabolism. As the characterization of these disorders at the clinical and biochemical levels has progressed rapidly, so has the delineation of the molecular defects that underlie them. The most commonly recognized disorder of beta-oxidation is medium-chain acyl-CoA dehydrogenase deficiency; a striking feature of this disorder is that there is a single point mutation that accounts for 90% of the variant alleles among patients with medium-chain acyl-CoA dehydrogenase deficiency. Molecular defects of other enzymes in the pathway have been identified, and it seems likely that a complete description of these defects at the molecular level is a realistic goal. In basic biological terms, such studies will lead to a better understanding of the genetic control exerted on this pathway. In clinical terms, they will lead to improved understanding of the molecular pathophysiology of these diseases and may well provide the necessary techniques to proceed with the screening of these disorders.http://www.sciencedirect.com/science/article/pii/S002222752040762X
collection DOAJ
language English
format Article
sources DOAJ
author PM Coates
K Tanaka
spellingShingle PM Coates
K Tanaka
Molecular basis of mitochondrial fatty acid oxidation defects.
Journal of Lipid Research
author_facet PM Coates
K Tanaka
author_sort PM Coates
title Molecular basis of mitochondrial fatty acid oxidation defects.
title_short Molecular basis of mitochondrial fatty acid oxidation defects.
title_full Molecular basis of mitochondrial fatty acid oxidation defects.
title_fullStr Molecular basis of mitochondrial fatty acid oxidation defects.
title_full_unstemmed Molecular basis of mitochondrial fatty acid oxidation defects.
title_sort molecular basis of mitochondrial fatty acid oxidation defects.
publisher Elsevier
series Journal of Lipid Research
issn 0022-2275
publishDate 1992-08-01
description A dozen separate inherited disorders of mitochondrial fatty acid beta-oxidation have been described in humans. This represents about half of the potential sites for genetic error that can affect this important pathway of energy metabolism. As the characterization of these disorders at the clinical and biochemical levels has progressed rapidly, so has the delineation of the molecular defects that underlie them. The most commonly recognized disorder of beta-oxidation is medium-chain acyl-CoA dehydrogenase deficiency; a striking feature of this disorder is that there is a single point mutation that accounts for 90% of the variant alleles among patients with medium-chain acyl-CoA dehydrogenase deficiency. Molecular defects of other enzymes in the pathway have been identified, and it seems likely that a complete description of these defects at the molecular level is a realistic goal. In basic biological terms, such studies will lead to a better understanding of the genetic control exerted on this pathway. In clinical terms, they will lead to improved understanding of the molecular pathophysiology of these diseases and may well provide the necessary techniques to proceed with the screening of these disorders.
url http://www.sciencedirect.com/science/article/pii/S002222752040762X
work_keys_str_mv AT pmcoates molecularbasisofmitochondrialfattyacidoxidationdefects
AT ktanaka molecularbasisofmitochondrialfattyacidoxidationdefects
_version_ 1721508252374532096